EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Melanosis Secondary to Drugs: A Real‐World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Yilin Zhao, Hanzhang Xie, Zhanshuo Xiao, Yansong Zhao

Skin Research and Technology · 2025

DOI: 10.1111/srt.70234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Skin Research and Technology, 2025. Verfasst von Yilin Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Melanosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: High Level Chinese Medical Hospital, Escort Project of Guang'anmen Hospital, China Academy of Chinese Medicine Science-Backbone Talent, Scientific Research Foundation for New recruits, China Academy of Chinese Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanosis is an acquired hyperpigmentation disorder that can be associated with the use of medications; timely identification and discontinuation of relevant medications is an important aspect of clinical management.

Objective

This study investigates the relationship between melanosis and drug exposure based on data from the FDA Adverse Event Reporting System (FAERS) database. We sought to determine the top drugs reported in association with melanosis in the FAERS.

Methods

A retrospective analysis of FAERS data from January 2004 to June 2024 was conducted to identify reports related to melanosis, using the Comprehensive Medical Dictionary for Regulatory Activities (MedDRA) terminology. A total of 18 182 912 independent adverse event reports were processed, and signal mining analyses were performed to detect associations between drugs and melanosis. Disproportionality analyses were conducted using four algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi‐item gamma Poisson shrinker (MGPS). The most frequently reported drugs and their associated adverse event reports were analyzed.

Results

Hundred and one reports related to melanosis were screened, involving 73 drug names as primary suspect (PS). By combining and organizing the different names of drugs such as trade names and generic names, 66 drugs were obtained. The top five drugs associated with melanosis were talimogene laherparepvec (ROR: 1891.39), followed by ferrous sulfate (ROR: 997.14), minocycline (ROR: 176.05), vemurafenib (ROR: 97.64), and pembrolizumab (ROR: 19.73).

Conclusion

Patients who experience drug‐induced melanosis generally have bad outcomes, underscoring the imperative for heightened clinical surveillance regarding the risk of drug‐induced melanosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsMelanosisUnited StatesHumansRetrospective StudiesMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overOdds RatioProportional Hazards ModelsBayes TheoremPoisson DistributionNeural Networks, ComputerPharmacovigilanceUnited States Food and Drug AdministrationMinocyclineVemurafenib

Stichwörter der Autor:innen

FAERSadverse eventcutaneous melanosisdrug‐induced cutaneous melanosismelanosispharmacovigilance study

Substanzen

talimogene laherparepvecferrous sulfateMinocyclineVemurafenibpembrolizumabBiological ProductsFerrous CompoundsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Beijing University of Chinese Medicine, Beijing, China.
  • Department of Dermatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Förderung

  • High Level Chinese Medical Hospital
  • Escort Project of Guang'anmen Hospital, China Academy of Chinese Medicine Science-Backbone Talent
  • Scientific Research Foundation for New recruits, China Academy of Chinese Medical Sciences

Zitieren

APA

Zhao, Y., Xie, H., Xiao, Z., & Zhao, Y. (2025). Melanosis Secondary to Drugs: A Real‐World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Skin Research and Technology. https://doi.org/10.1111/srt.70234

Vancouver

Zhao Y, Xie H, Xiao Z, Zhao Y. Melanosis Secondary to Drugs: A Real‐World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Skin Research and Technology. 2025. doi:10.1111/srt.70234

BibTeX
@article{Zhao2025,
  author = {Zhao, Yilin and Xie, Hanzhang and Xiao, Zhanshuo and Zhao, Yansong},
  title = {Melanosis Secondary to Drugs: A Real‐World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)},
  journal = {Skin Research and Technology},
  year = {2025},
  doi = {10.1111/srt.70234}
}
Kostenlos starten →